Compare DSP & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSP | OBIO |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.9M | 238.9M |
| IPO Year | 2021 | 2020 |
| Metric | DSP | OBIO |
|---|---|---|
| Price | $11.43 | $3.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $17.81 | $14.25 |
| AVG Volume (30 Days) | 237.0K | ★ 521.0K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.14 | 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $344,201,000.00 | $33,482,000.00 |
| Revenue This Year | $20.27 | N/A |
| Revenue Next Year | $16.88 | $12.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 19.00 | ★ 1169.22 |
| 52 Week Low | $8.11 | $2.20 |
| 52 Week High | $15.18 | $5.42 |
| Indicator | DSP | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.31 | 39.82 |
| Support Level | $10.77 | $3.47 |
| Resistance Level | $12.61 | $4.18 |
| Average True Range (ATR) | 0.77 | 0.26 |
| MACD | -0.11 | -0.05 |
| Stochastic Oscillator | 4.57 | 5.05 |
Viant Technology Inc is an advertising technology company engaged in providing a cloud-based demand-side platform (DSP) for programmatic advertising. The company enables marketers and advertising agencies to plan, buy, and measure digital advertising campaigns across multiple channels, including connected TV, streaming audio, mobile, desktop, and digital out-of-home. Its platform leverages data integrations and proprietary identity solutions to deliver targeted advertising, audience insights, and performance measurement.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.